TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade

Cancer Letters

Volumn 313, Issue 2, 2011, Pages 211-217

  Zha, Xiaojun ^a,b,c   Hu, Zhongdong ^a   He, Shaozong ^a   Wang, Fang ^a   Shen, Huangxuan ^d   Zhang, Hongbing ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c State Key Laboratory Incubation Base of Dermatology   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Benign tumor; MTORC1; PTEN; STAT3; TSC

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; STAT3 PROTEIN; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DOWN-REGULATION; HUMANS; MICE; PROMOTER REGIONS, GENETIC; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

MAMMALIA;

EID: 82655168783     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.006     Document Type: Article

References (31)

1. Orlova K.A., Crino P.B. The tuberous sclerosis complex. Ann. NY Acad. Sci. 2010, 1184:87-105.
2. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N. Engl. J. Med. 2006, 355:1345-1356.
3. Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17:1829-1834.
4. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
5. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15:356-362.
6. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
7. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., Dixon J.E., Pandolfi P., Pavletich N.P. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99:323-334.
8. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390.
9. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
10. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
11. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., Vazquez F., Carpenter C.L., Kwiatkowski D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 2003, 112:1223-1233.
12. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., Griffin J.D., Kwiatkowski D.J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 2007, 117:730-738.
13. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downes C.P., Lamb R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166:213-223.
14. Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004, 14:1650-1656.
15. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., Darnell J.E. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 1998, 18:2553-2558.
16. El-Hashemite N., Zhang H., Walker V., Hoffmeister K.M., Kwiatkowski D.J. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res. 2004, 64:3436-3443.
17. Ma J., Meng Y., Kwiatkowski D.J., Chen X., Peng H., Sun Q., Zha X., Wang F., Wang Y., Jing Y., Zhang S., Chen R., Wang L., Wu E., Cai G., Malinowska-Kolodziej I., Liao Q., Liu Y., Zhao Y., Xu K., Dai J., Han J., Wu L., Zhao R.C., Shen H., Zhang H. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J. Clin. Invest. 2010, 120:103-114.
18. Meikle L., Talos D.M., Onda H., Pollizzi K., Rotenberg A., Sahin M., Jensen F.E., Kwiatkowski D.J. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 2007, 27:5546-5558.
19. Chong-Kopera H., Inoki K., Li Y., Zhu T., Garcia-Gonzalo F.R., Rosa J.L., Guan K.L. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem. 2006, 281:8313-8316.
20. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., Yang Q., Bennett C., Harada Y., Stankunas K., Wang C.Y., He X., MacDougald O.A., You M., Williams B.O., Guan K.L. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
21. Duvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., Vander Heiden M.G., MacKeigan J.P., Finan P.M., Clish C.B., Murphy L.O., Manning B.D. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
22. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
23. Onda H., Crino P.B., Zhang H., Murphey R.D., Rastelli L., Gould Rothberg B.E., Kwiatkowski D.J. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell. Neurosci. 2002, 21:561-574.
24. Yu Y., Yoon S.O., Poulogiannis G., Yang Q., Ma X.M., Villen J., Kubica N., Hoffman G.R., Cantley L.C., Gygi S.P., Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332:1322-1326.
25. Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
26. Manning B.D., Logsdon M.N., Lipovsky A.I., Abbott D., Kwiatkowski D.J., Cantley L.C. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 2005, 19:1773-1778.
27. Ma L., Teruya-Feldstein J., Behrendt N., Chen Z., Noda T., Hino O., Cordon-Cardo C., Pandolfi P.P. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 2005, 19:1779-1786.
28. Mahimainathan L., Ghosh-Choudhury N., Venkatesan B., Das F., Mandal C.C., Dey N., Habib S.L., Kasinath B.S., Abboud H.E., Ghosh Choudhury G. TSC2 deficiency increases PTEN via HIF1alpha. J. Biol. Chem. 2009, 284:27790-27798.
29. Stambolic V., MacPherson D., Sas D., Lin Y., Snow B., Jang Y., Benchimol S., Mak T.W. Regulation of PTEN transcription by p53. Mol. Cell 2001, 8:317-325.
30. Zha X., Wang F., Wang Y., He S., Jing Y., Wu X., Zhang H. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res. 2011, 71:13-18.
31. Zha X., Sun Q., Zhang H. mTOR upregulation of glycolytic enzymes promotes tumor development. Cell Cycle 2011, 10:1015-1016.